Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8785292 | Brachytherapy | 2018 | 7 Pages |
Abstract
For medically inoperable patients with early-stage primary or local posttreatment residual or recurrent EC, EHDRBT is a well-tolerated treatment option with minimal Grade â¥3 toxicity. Brachytherapy in our hands continues to be a safe treatment option. Although 58.6% of patients achieved a complete response and the OS of this cohort is relatively good, long-term local control and cure remains a challenge.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Amandeep S. Taggar, Kenneth L. Pitter, Gil'ad N. Cohen, Mark Schattner, Hans Gerdes, Arnold J. Markowitz, David Ilson, Paul Brady, John J. Cuaron, Karyn A. Goodman, Abraham J. Wu,